{"organizations": [], "uuid": "2c37ed736a1a0d7a2ffa80e6c4afb2c2295c7ac3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eylea-injection-demonstrates-posit/brief-eylea-injection-demonstrates-positive-topline-results-in-phase-3-non-proliferative-diabetic-retinopathy-trial-idUSASC09SQW", "country": "US", "domain_rank": 408, "title": "BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T13:14:00.000+02:00", "replies_count": 0, "uuid": "2c37ed736a1a0d7a2ffa80e6c4afb2c2295c7ac3"}, "author": "", "url": "https://www.reuters.com/article/brief-eylea-injection-demonstrates-posit/brief-eylea-injection-demonstrates-positive-topline-results-in-phase-3-non-proliferative-diabetic-retinopathy-trial-idUSASC09SQW", "ord_in_thread": 0, "title": "BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "regeneron pharma", "sentiment": "none"}, {"name": "non-proliferative diabetic retinopathy trial reuters", "sentiment": "none"}, {"name": "regeneron", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "none"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 14 AM / Updated 11 minutes ago BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial Reuters Staff March 19 (Reuters) - Regeneron Pharmaceuticals Inc: * EYLEAÂ® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL * REGENERON PHARMA-PHASE 3 TRIAL EVALUATING EYLEA INJECTION IN MODERATELY SEVERE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY MET PRIMARY ENDPOINT * REGENERON PHARMA - 58 PERCENT OF EYLEA-TREATED PATIENTS EXPERIENCED TWO-STEP OR GREATER IMPROVEMENT FROM BASELINE ON DIABETIC RETINOPATHY SEVERITY SCALE (DRSS) AT WEEK 24 * REGENERON PHARMACEUTICALS INC - THERE WAS ONE CASE OF MILD INTRAOCULAR INFLAMMATION (IOI) IN A PATIENT TREATED WITH EYLEA IN TRIAL * REGENERON PHARMACEUTICALS - EXPECT U.S. REGULATORY SUBMISSION FOR DIABETIC RETINOPATHY LATER THIS YEAR Source text for Eikon:  ", "external_links": [], "published": "2018-03-19T13:14:00.000+02:00", "crawled": "2018-03-19T13:27:52.079+02:00", "highlightTitle": ""}